๐Ÿ”Ž Trials Near Me

Home โ€บ Glioma

Glioma clinical trials recruiting in the U.S.

118 studies for Glioma are recruiting participants at sites across the United States.

Cities with the most studies

By state

Recently updated studies

A Study of Mirdametinib in People With Central Nervous System Tumors

RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Nov 13, 2026 ยท NCT07539441

000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

RecruitingPhase 1/2
Ages 15 to 99 ยท All sexes ยท Updated Nov 12, 2026 ยท NCT05588141

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Nov 12, 2026 ยท NCT07326566

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma

Recruiting
Ages 18 to 85 ยท All sexes ยท Updated Nov 12, 2026 ยท NCT06910306

Observational Connectomics in Adults Undergoing Resection of WHO II-IV Glioma

RecruitingObservational study
Ages 18 and older ยท All sexes ยท Updated Nov 10, 2026 ยท NCT07927595

A Phase I Clinical Study of YN003 in the Treatment of Glioma

RecruitingPhase 1
Ages 18 to 70 ยท All sexes ยท Updated Nov 10, 2026 ยท NCT07929909

Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Nov 10, 2026 ยท NCT07703436

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

RecruitingPhase 1/2
Ages 18 to 120 ยท All sexes ยท Updated Nov 6, 2026 ยท NCT06161519

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Nov 4, 2026 ยท NCT07464925

Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma

RecruitingEarly phase 1
Ages 18 and older ยท All sexes ยท Updated Nov 4, 2026 ยท NCT05717153

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

RecruitingPhase 2
Up to age 3 ยท All sexes ยท Updated Nov 3, 2026 ยท NCT06528691

Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being

Recruiting
Ages 18 and older ยท All sexes ยท Updated Nov 3, 2026 ยท NCT07628647

Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas

RecruitingEarly phase 1
Ages 18 and older ยท All sexes ยท Updated Nov 2, 2026 ยท NCT05804227

A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)

RecruitingPhase 1
Ages 4 and older ยท All sexes ยท Updated Oct 30, 2026 ยท NCT04573140

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Oct 27, 2026 ยท NCT05916313

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

RecruitingPhase 2
12 Months โ€“ 39 Years ยท All sexes ยท Updated Oct 23, 2026 ยท NCT06838676

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Oct 21, 2026 ยท NCT06810544

Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment

RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Oct 21, 2026 ยท NCT05460507

Development of MRF for Characterization of Brain Tumors After Radiotherapy

RecruitingHealthy volunteers welcome
Ages 18 to 60 ยท All sexes ยท Updated Oct 20, 2026 ยท NCT06101069

Tumor Treating Fields for the Treatment of Brainstem Gliomas

Recruiting
Ages 18 and older ยท All sexes ยท Updated Oct 19, 2026 ยท NCT05310448

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Oct 19, 2026 ยท NCT05303519

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

RecruitingPhase 1/2
Ages 18 to 99 ยท All sexes ยท Updated Oct 16, 2026 ยท NCT07416188

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

RecruitingPhase 1
Ages 18 to 120 ยท All sexes ยท Updated Oct 16, 2026 ยท NCT06344130

A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions

RecruitingEarly phase 1
Ages 18 and older ยท All sexes ยท Updated Oct 16, 2026 ยท NCT06072586

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.